fashion -WSS

fashion

author：entertainment 2025-09-27 15:35:27 - browse：557

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Caribou posts encouraging results on off

leisure time

WSS

Menendez indictment could see pharma lose a key ally

A new ‘biological computer' targets cancer while sparing healthy cells

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Extensive review finds private equity owners jack up cost of care

Scientists grapple with ethics of stem cell research

Cigna to pay $172 million to settle Medicare Advantage fraud probe

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

When a patient nears the end, a feared therapy can comfort

Anesthesiologist group: stop taking Ozempic before surgery

Sanders wants to replace patents with prizes for drug inventions

Alkermes shareholders re

Judge denies Trump's request for new trial in E. Jean Carroll case

As demand for Covid shots wanes, Moderna seeks its next success

How the Dana

United colonoscopy coverage change 'may cost lives,' doctors say

There’s a way to spot data fakery. All journals should be using it

explore

Sudafed saga points to U.S. issues with evaluating older drugs

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Covid vaccines: Private market messier than government rollout

FDA seeks to regulate lab

Address the ethical violations that led to 'Three Identical Strangers'

Telehealth startups are trying to fill the menopause care vacuum

focus

leisure time

knowledge

Wikipedia